% | $
Quotes you view appear here for quick access.

Alexza Pharmaceuticals Inc. Message Board

  • cabogordon cabogordon May 8, 2013 10:48 AM Flag


    May 8, 2013
    10:36 EDT ALXA
    theflyonthewall: Alexza deal with Teva could be worth $12 per share or more, says Roth Capital
    After Teva (TEVA) agreed to market Alexza's (ALXA) Adasuve - an acute treatment of agitation associated with schizophrenia or bipolar disorder - in the U.S., Roth Capital thinks the deal could be worth about $12 per share or more to Alexza. The firm thinks the deal has several positive aspects for Alexza, including a $40M upfront cash payment, a reduction of risk, and validation of the drug. The firm keeps a Buy rating on the stock

0.9531-0.0075(-0.78%)May 27 4:00 PMEDT